MarketCap
Facebook
X
TelegramAlexion Pharmaceuticals, Inc. Income Statement 2020-2011 | ALXN
Brief overview of financial performance at Alexion Pharmaceuticals, Inc.
The overview follows changes across a five-year period. Revenue reported by Alexion Pharmaceuticals, Inc. was $2.6 billion at the beginning of the period and $6.1 billion at the end. Across the full period, sales moved by +133.1%; the average annual rate was 18.4%. Top-line growth remained consistently strong over the period.
The gross result shifted from $2.4 billion to $5.5 billion, or +132.7%. Gross profit as a share of revenue changed from 91% to 90.9%. Gross profitability remained broadly stable.
The five-year EBITDA result moved by +289.7%: from 799 million dollars to 3.1 billion dollars. The operating result outpaced sales and points to improving efficiency. Comparing the endpoints gives EBITDA margins of 30.7% and 51.3%. The business generated more EBITDA from each unit of revenue.
Over the period, net income shifted from 144 million dollars to 603 million dollars (+317.9%). Net income grew faster than revenue, indicating improved overall efficiency.
The market value of the business moved from $31.1 billion to $33.6 billion, or +7.9%. The financial trend was stronger than the market valuation.
Financial takeaway
The five-year financial profile is predominantly positive. The positive side is supported by sales growth, steady gross profitability and higher operating efficiency. The key question is whether sales can be converted into sustainable profit.
Annual Income Statement Alexion Pharmaceuticals, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
33.6 B | 22.4 B | 27 B | 27.4 B | 28.7 B | 31.1 B | 36.3 B | 31.7 B | 18.2 B | 13.7 B |
Shares |
219 M | 223 M | 223 M | 224 M | 224 M | 213 M | 198 M | 196 M | 190 M | 183 M |
Net Income |
603 M | 2.4 B | 77.6 M | 443 M | 399 M | 144 M | 657 M | 253 M | 255 M | 175 M |
Revenue |
6.07 B | 4.99 B | 4.13 B | 3.55 B | 3.08 B | 2.6 B | 2.23 B | 1.55 B | 1.13 B | 783 M |
EBITDA |
3.11 B | 2.45 B | 1.91 B | 1.12 B | 1.12 B | 799 M | 963 M | 567 M | 454 M | 245 M |
Operating Expenses |
2.66 B | 2.46 B | 2.16 B | 2.29 B | 2.03 B | 1.69 B | 1.14 B | 807 M | 608 M | 446 M |
General and Administrative Expenses |
1.4 B | 1.26 B | 1.11 B | 1.09 B | 954 M | 863 M | 630 M | 490 M | 385 M | 308 M |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Alexion Pharmaceuticals, Inc. (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
Canada
China
France
Germany
Israel
Britain
Russia
Belgium
Cayman-islands
